Comparison Among Erythropoietin Stimulating Agents
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
* Background: Despite extensive use, to the best of our knowledge, no trial has
simultaneously compared the three currently used erythropoietin stimulating agents (ESAs) in
a prospective manner, in treatment of anemia of end stage renal disease (ESRD) patients.
* Patients and Methods: All haemodialysis patients in Qatar who were treated with short
acting Epoetin alfa or beta were screened. Eligible patients were randomized, either to
continue on the previous regimen of Epoetin, or to receive Darbepoetin alfa or continuous
erythropoietin receptor activator (C.E.R.A) for a total period of 40 weeks. All groups were
assessed at the end of the study for safety and efficacy parameters.